A study conducted to determine if a single dose of 25 mg. of psilocybin, in combination with therapy, will address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission

Who can Participate

Female adults with early-stage breast cancer or late-stage ovarian cancer who have a fear of recurrence. **Target population: Female adults with early-stage breast cancer at low risk for recurrence and late-stage ovarian cancer at high risk for recurrence **Patients with diagnosis of cancer who may have recently completed surgical or chemotherapy **General overall ability to function and care for self **Screening and baseline score on the Fear of Recurrence Inventory > 16

Study ID

More information available at ClinicalTrials.gov: NCT06430541